title: Phase I results from a two-part Phase I/II study of cediranib in combination with mFOLFOX6 in Japanese patients with metastatic colorectal cancer.
abstract: BACKGROUND
  Colorectal cancer (CRC) is the second most common malignancy in Japan. Inhibition of vascular endothelial growth factor (VEGF) signaling is a clinically validated therapeutic strategy in patients with metastatic CRC. Cediranib is an oral, highly potent VEGF signaling inhibitor of all three VEGF receptors.
  
  
  METHODS
  This Phase I study investigated the safety, tolerability and pharmacokinetics of cediranib (20 or 30 mg) in combination with mFOLFOX6 in Japanese patients with previously untreated metastatic CRC. If the safety of the 20 mg dose was confirmed, a second cohort of patients was to be recruited to receive cediranib 30 mg + mFOLFOX6.
  
  
  RESULTS
  Six patients received cediranib 20 mg + mFOLFOX6 and seven received cediranib 30 mg + mFOLFOX6. One patient in the initial cediranib 20 mg cohort experienced a dose-limiting toxicity (DLT; grade 3 bilirubin increase); no DLTs were observed in the 30 mg cohort. The most commonly reported adverse events were diarrhea, decreased appetite, peripheral neuropathy, hypertension and fatigue. Two patients in the 20 mg cohort and three in the 30 mg cohort experienced serious adverse events during all treatment courses. Cediranib was generally well tolerated in this patient population with no evidence to suggest any significant pharmacokinetic interactions between cediranib and fluorouracil or oxaliplatin. A preliminary evaluation showed that five of nine evaluable patients achieved a best response of partial response.
  
  
  CONCLUSIONS
  Cediranib (20 or 30 mg) in combination with mFOLFOX6 was considered tolerable according to the protocol-defined criteria, providing justification for the Phase II part of this study.
authors: Kinki University School of Medicine, Osaka, Japan. tarohsatoh@hotmail.com
authors: Taroh
authors: T
authors: Satoh
authors: Kensei
authors: K
authors: Yamaguchi
authors: Narikazu
authors: N
authors: Boku
authors: Wataru
authors: W
authors: Okamoto
authors: Tomotaka
authors: T
authors: Shimamura
authors: Kentaro
authors: K
authors: Yamazaki
authors: Xiaojin
authors: X
authors: Shi
authors: Hideyuki
authors: H
authors: Mishima
references: Cancer Chemother Pharmacol. 2009 Nov;64(6):1165-72
references: 19308410
references: Jpn J Clin Oncol. 2010 Mar;40(3):194-202
references: 19897852
references: N Engl J Med. 2005 Feb 3;352(5):476-87
references: 15689586
references: Clin Colorectal Cancer. 2009 Jan;8(1):59-60
references: 19203899
references: Cancer Res. 2005 May 15;65(10):4389-400
references: 15899831
references: Eur J Cancer. 2010 Mar;46(5):901-11
references: 20061136
references: J Clin Oncol. 2008 Apr 10;26(11):1871-8
references: 18398152
references: J Clin Oncol. 2004 Jan 1;22(1):23-30
references: 14665611
references: N Engl J Med. 2004 Jun 3;350(23):2335-42
references: 15175435
references: J Clin Oncol. 2007 Jul 20;25(21):3045-54
references: 17634482
references: Eur J Cancer. 2009 Mar;45(5):782-8
references: 19091548
references: Jpn J Clin Oncol. 2007 Oct;37(10):755-62
references: 17951335
references: Invest New Drugs. 2011 Dec;29(6):1395-405
references: 20607586
references: Clin Cancer Res. 2009 Feb 15;15(4):1481-6
references: 19228749
references: Cancer Res. 2008 Jun 15;68(12):4754-62
references: 18559522